At BioPep, we believe that better health is achievable through safe, scientifically tested organopeptides. We utilize organopeptides manufactured by European Wellness Biomedical Group (EW) at the manufacturing facility in Europe to ensure that all organopeptide products are pathogen-free and safe. These organopeptides, which are Nano Organo Peptides or Mito Organelles (NOPs and MOs), are being used to rejuvenate and improve animal health. 

In a recently published study in the Open Access Journal of Biomedical Science our scientists have shown that our NOPs and MOs can improve the reproductive health in canines (dogs). 

In this study, we hypothesized that peptide therapy could improve fertility in canines. Improving fertility and reproductive health in mammals is important for several reasons, including protecting the genetic diversity of species. 

Following on from our promising earlier regenerative results in pre-clinical models, this case study was done using four Shiloh Shepherd canines to assess their responses to the MO injection protocols developed and tested by BioPep. The canines’ hormonal levels were monitored from the start of estrus to identify and facilitate the optimum fertile time for breeding.

Subject A, a 5-year-old rare breed Shiloh Shepherd had previously been bred once, which resulted in a single live birth. Since then, her heat cycles were erratic, with an unpredictable amount of time between each estrus. 

Subject B, a 5-year-old rare breed Shiloh Shepherd, and sibling to Subject A, had previously been bred once, which had resulted in seven live births. Since then, her heat cycles were erratic, with an unpredictable amount of time between each estrus. 

We started NOP injections were started to bring Subjects A and B into estrus (menstruation) to make them fertile. Both began estrus, and their progesterone levels were monitored to identify and facilitate the optimum time to breed. 

Subject C, a 4-year-old rare breed Shiloh Shepherd had previously been bred twice naturally, and the third time with peptide treatments. The first litter resulted in 2 viable pups (without peptide treatment), and the second litter (without peptide treatment) resulted in 5 live births. The third litter following peptide treatment resulted in 9 live pups.

Subject D, a 7-year-old champion pure breed Collie had been bred three times. The first breeding had previously resulted in a single stillborn pup, and the second breeding had resulted in three live male puppies. She had no estrus in 3 years and, following the peptide injections, had a rapid increase in progesterone levels, with no adverse effects observed. With organ-specific peptide treatment, she produced a single, live birth. 

For Subjects A, B, and D, the course of peptide therapy appeared to help normalize the estrus cycle, making it occur at a more regular interval than previously observed. Following MO peptide therapy, Subject C produced a litter of 9 pups, and Subject D produced a single pup.

This case study shows that peptide therapy can induce an estrus cycle and possibly increase the litter number of puppies. It suggests an important role for peptide therapy in improving canine reproductive health and fertility that should be further investigated.

Though limited conclusions can be drawn from this small case study, it suggests a promising role for peptide therapy using Nano Organo Peptides/Mito Organelles (NOPs and MOs) in canine fertility and thus improves animal health. 

Additionally, no adverse effects were observed in this case study, suggesting that these organopeptides are both safe and effective. Future studies will need to be done to increase the number of canine subjects and further, study any effects on male canines. 

At BioPep, we partner with top-tier research institutions, universities, and manufacturing facilities to provide data on the effectiveness of organ-specific peptides’ ability to rejuvenate and heal. This promising study could also pave the way for peptide therapy research in the reproductive health of other mammals beyond canines.

Augusta W, Jonathan RTL, Alana W, Mike KSC, Michelle BFW, Marcelle Gisain, Caroline Mosessain, Orn Adalsteinsson, Desiree C.T. Cox, Case Study: Efficacy Trial for Peptide Treatment for Fertility. 2022- 4(4) OAJBS.ID.000469. DOI: 10.38125/OAJBS.000469

Similar Posts